SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pharmos (PARS)
An SI Board Since October 1998
Posts SubjectMarks Bans Symbol
1386 42 0 PARS
Emcee:  Dr. John M. de Castro Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1161Pharmos Reports Significant Brain Recovery in Stroke Models Using Dexanabinol - leigh aulper-11/7/2000
1160Pharmos Announces Record Quarterly Revenues in Fiscal Third Quarter; Internationleigh aulper-10/17/2000
1159Pharmos Presents New Analysis of Phase II Head Trauma Trial Positive Results Obtleigh aulper-9/27/2000
1158Pharmos Raises $11 Million in Private Transaction; Increased Cash Position to beleigh aulper-9/6/2000
1157RON I return to this thread and like you very little posting.at least Pharmos upGabe Fernandez-9/4/2000
1156Pharmos Licenses Ophthalmic Formulation to Senju Pharmaceutical Co. in Japan Agrleigh aulper-8/29/2000
1155A big pharma parstner in one of the drugs, but: 1. Worldwide partner for the eyCacaito-8/1/2000
1154And Pharmos ends up 1/32 up for the day after this news. Can anyone out there teNoel de Leon-7/31/2000
1153nice growth Pharmos Reports 65% Sales Growth in 2000 Second Quarter; Quarterly Lleigh aulper-7/31/2000
1152Pharmos Reports Progress in Dexanabinol Program Presents R&D Results in Inteleigh aulper-7/26/2000
1151Some good revenues would be nice. The recent rise in the price has to be due toMichael Casey-7/24/2000
1150From BOL 2Q report: ""Second-quarter revenues from the company's pCacaito-7/24/2000
1149AS a shareholder, I continue to lrk. I do not know anything about the science, eStephen Krupa-7/1/2000
1148Does anybody read this thread? Yosi? David? et all?Ron-7/1/2000
1147 I had been an unrelenting long holder of PARS. My average cost per share was $Stephen D. Wilson-6/19/2000
1146 I think that what is more important than the number of shares that were sold isShamukE-6/15/2000
1145 I just hope they wanted to get off a hamburger diet. John T. Hardee-6/14/2000
1144 Seriously considering a speculative investment in PARS. Any thoughts on the sigLiPolymer-6/13/2000
1143 How sweet it is,,, the news.. thanks for the postJohn T. Hardee-6/13/2000
1142 Pharmos Appoints Quintiles to Manage European Phase III Clinical Trial; Agreemeleigh aulper-6/13/2000
1141 I see where Bausch & Lomb also collaborates in the development of producJohn T. Hardee-5/25/2000
1140 I think the more marijuana and its derivatives and analogs are approved for medj_fir2-5/16/2000
1139 Yosi, David...someone? Will any of you be listening in on the conference call?Ron-5/5/2000
1138 Friday May 5, 8:36 am Eastern Time Company Press Release SOURCE: Pharmos CorporJohn T. Hardee-5/5/2000
1137 Just a quick hello to all of you.Ron-5/3/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News